Onconetix registered up to 100,000,000 common shares for resale by Seven Knots LLC at prevailing market prices or privately negotiated prices. The company will receive no proceeds from the sales, while the shares could increase common stock outstanding to 104,380,522 if fully issued upon conversion of Series F preferred stock.
Key Highlights
- Onconetix could have 104,380,522 common shares outstanding if all registered shares are issued.
- Seven Knots LLC held 230,068 shares and reported 4.99% beneficial ownership before the offering.
- Onconetix registered up to 100,000,000 common shares for resale by Seven Knots.
- The company will receive no proceeds from the resales.
Onconetix, Inc. (NASDAQ: ONCO) registered up to 100,000,000 common shares for resale by a Selling Stockholder at prevailing market prices or privately negotiated prices. The company will receive no proceeds from those sales. The shares are issuable only through conversion of part of the 37,812 Series F Preferred Shares issued to the Selling Stockholder. If all 100,000,000 shares are issued, Onconetix’s common stock outstanding would rise from 4,380,522 shares to 104,380,522 shares. The registered amount would represent 2,282% of the aggregate common shares outstanding as of August 28, 2026.
100M Shares Registered
Seven Knots held 230,068 shares before the offering and reported beneficial ownership of 4.99%. The holder may sell all, some or none of the registered shares through the Nasdaq Capital Market, another exchange, a market or trading facility, or private transactions. Onconetix also stated that it does not currently have enough authorized but unissued common shares to register every share issuable upon conversion of that preferred stock.
Conversion Terms Set Resale Scope
That amount was satisfied partly in cash and partly through cancellation of commitment fees owed to the Selling Stockholder. Only the Series F-related shares covered by the resale registration are included in this offering.
Market Or Negotiated Pricing
The Selling Stockholder may set the resale price at a fixed amount, a prevailing market price, a price linked to the market price, or a privately negotiated price. The price determination references the company’s financial condition and prospects, its limited operating history and the general securities market. Onconetix’s amended and restated certificate of incorporation authorizes up to 250,000,000 common shares with a $0.00001 Par Value per share. It also authorizes 10,000,000 preferred shares with a $0.00001 par value.
No Company Proceeds
Onconetix will not receive proceeds from any resale conducted by the Selling Stockholder. The company will pay expenses connected with the share sales, excluding Underwriting discounts and commissions. Seven Knots’ stated post-offering beneficial ownership is 5,482,147 shares and 4.99%.






Please wait processing your request...